1887

Abstract

Reports have shown that oleanolic acid (OA), a triterpenoid, exists widely in food, medicinal herbs and other plants, and that it has antimycobacterial activity against the strain H37Rv (ATCC 27294). In this study it was found that OA had antimycobacterial properties against eight clinical isolates of and that the MICs of OA against drug-sensitive and drug-resistant isolates were 50–100 and 100–200 μg ml, respectively. The combination of OA with isoniazid (INH), rifampicin (RMP) or ethambutol (EMB) showed favourable synergistic antimycobacterial effects against six drug-resistant strains, with fractional inhibitory concentration indices of 0.121–0.347, 0.113–0.168 and 0.093–0.266, respectively. The combination treatments of OA/INH, OA/RMP and OA/EMB displayed either a synergistic interaction or did not show any interaction against two drug-sensitive strains. No antagonism resulting from the OA/INH, OA/RMP or OA/EMB combination was observed for any of the strains tested. OA exhibited a relatively low cytotoxicity in Vero cells. These results indicate that OA may serve as a promising lead compound for future antimycobacterial drug development.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.014837-0
2010-05-01
2024-12-10
Loading full text...

Full text loading...

/deliver/fulltext/jmm/59/5/567.html?itemId=/content/journal/jmm/10.1099/jmm.0.014837-0&mimeType=html&fmt=ahah

References

  1. Bamuamba K., Gammon D. W., Meyers P., Dijoux-Franca M. G., Scott G. 2008; Anti-mycobacterial activity of five plant species used as traditional medicines in the Western Cape Province (South Africa). J Ethnopharmacol 117:385–390 [CrossRef]
    [Google Scholar]
  2. Banno N., Akihisa T., Tokuda H., Yasukawa K., Higashihara H., Ukiya M., Watanabe K., Kimura Y., Hasegawa J., Nishino H. 2004; Triterpene acids from the leaves of Perilla frutescens and their anti-inflammatory and antitumor-promoting effects. Biosci Biotechnol Biochem 68:85–90 [CrossRef]
    [Google Scholar]
  3. Bloom B. R., Murray C. J. 1992; Tuberculosis: commentary on a reemergent killer. Science 257:1055–1064 [CrossRef]
    [Google Scholar]
  4. Caldwell C. G., Franzblau S. G., Suarez E., Timmermann B. N. 2000; Oleanane triterpenoids from Junellia tridens . J Nat Prod 63:1611–1614 [CrossRef]
    [Google Scholar]
  5. De Logu A., Onnis V., Saddi B., Congiu C., Schivo M. L., Cocco M. T. 2002; Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis . J Antimicrob Chemother 49:275–282 [CrossRef]
    [Google Scholar]
  6. De Logu A., Saddi M., Onnis V., Sanna C., Congiu C., Borgna R., Cocco M. T. 2005; In vitro antimycobacterial activity of newly synthesised S -alkylisothiosemicarbazone derivatives and synergistic interactions in combination with rifamycins against Mycobacterium avium . Int J Antimicrob Agents 26:28–32 [CrossRef]
    [Google Scholar]
  7. Deng J. Z., Starck S. R., Hecht S. M. 2000; Pentacyclic triterpenoids from Freziera sp. that inhibit DNA polymerase. Bioorg Med Chem 8:247–250 [CrossRef]
    [Google Scholar]
  8. Dye C. 2009; Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 7:81–87 [CrossRef]
    [Google Scholar]
  9. Gu J. Q., Wang Y., Franzblau S. G., Montenegro G., Timmermann B. N. 2004; Constituents of Quinchamalium majus with potential antitubercular activity. Z Naturforsch C 59:797–802
    [Google Scholar]
  10. Kent R. J., Bakhtiar M., Shanson D. C. 1992; The in-vitro bactericidal activities of combinations of antimicrobial agents against clinical isolates of Mycobacterium avium-intracellulare . J Antimicrob Chemother 30:643–650 [CrossRef]
    [Google Scholar]
  11. Koenig R. 2008; Drug-resistant tuberculosis: in South Africa, XDR TB and HIV prove a deadly combination. Science 319:894–897 [CrossRef]
    [Google Scholar]
  12. Kremer L. S., Besra G. S. 2002; Current status and future development of antitubercular chemotherapy. Expert Opin Investig Drugs 11:1033–1049 [CrossRef]
    [Google Scholar]
  13. Liu J. 1995; Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 49:57–68 [CrossRef]
    [Google Scholar]
  14. Mosmann T. 1983; Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63 [CrossRef]
    [Google Scholar]
  15. Newton S. M., Lau C., Wright C. W. 2000; A review of antimycobacterial natural products. Phytother Res 14:303–322 [CrossRef]
    [Google Scholar]
  16. Ovesna Z., Vachalkova A., Horvathova K., Tothova D. 2004; Pentacyclic triterpenoic acids: new chemoprotective compounds. Neoplasma 51:327–333
    [Google Scholar]
  17. Somova L. O., Nadar A., Rammanan P., Shode F. O. 2003; Cardiovascular, antihyperlipidemic and antioxidant effects of oleanolic and ursolic acids in experimental hypertension. Phytomedicine 10:115–121 [CrossRef]
    [Google Scholar]
  18. Stratton C. W., Cooksey R. C. 1991; Susceptibility tests: special tests. In The Manual of Clinical Microbiology , 5th edn. pp 1153–1165 Edited by Balows A., Hausler W. J. Jr, Hermann K. L., Isenberg H. D., Shadomy H. J. Washington, DC: American Society for Microbiology;
    [Google Scholar]
  19. Tanachatchairatana T., Bremner J. B., Chokchaisiri R., Suksamrarn A. 2008; Antimycobacterial activity of cinnamate-based esters of the triterpenes betulinic, oleanolic and ursolic acids. Chem Pharm Bull (Tokyo) 56:194–198 [CrossRef]
    [Google Scholar]
  20. WHO 2000; Anti-Tuberculosis Drug Resistance in the World. Report No. 2: Prevalence and Trends , WHO/CDS/TB/2000.278. Geneva: World Health Organization;
    [Google Scholar]
  21. WHO 2009 Global Tuberculosis Control: Epidemiology, Strategy, Financing , WHO/HTM/TB/2009.411 Geneva: World Health Organization;
    [Google Scholar]
  22. Yoon Y. H., Jung K. H., Sadun A. A., Shin H. C., Koh J. Y. 2000; Ethambutol-induced vacuolar changes and neuronal loss in rat retinal cell culture: mediation by endogenous zinc. Toxicol Appl Pharmacol 162:107–114 [CrossRef]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.014837-0
Loading
/content/journal/jmm/10.1099/jmm.0.014837-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error